Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Clinical Trials in the USA / NCT05820672
Recruiting Observational

A US Non-interventional, Effectiveness and Safety Study of Patients Treated With SKYTROFA

NCT05820672 · tracked via the Priya Life Science USA tracker
Sponsor
Ascendis Pharma Endocrinology Division A/S
Phase
Observational
Started
2023-03-20
Last updated
2026-04-21

Condition(s) studied

Growth Hormone Deficiency

Investigational drug(s) / intervention(s)

No intervention

No intervention: No intervention

Study summary

The goal of this study is to genrate evidence on long-term effectiveness and safety of SKYTROFA (lonapegsomatropin) in patients with growth hormone deficiency under routine clinical care

Eligibility

Sex
ALL
Min age
—
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Patients who are on treatment with SKYTROFA (lonapegsomatropin) * Patients being clinically managed in USA * Patients with an appropriate written informed consent/assent as applicable for the age of the patient Exclusion Criteria: * Patients participating in any interventional clinical study

Primary outcome measure(s)

  • Assess the safety of patients treated with SKYTROFA (Lonapegsomatropin) — 5 years
    Incidence of Adverse Events and Serious Adverse Events
  • Assess the effectiveness of patients treated with SKYTROFA (Lonapegsomatropin) — 5 years
    Near adult height (cm)

Trial sites (27)

FacilityCityRegionStatus
Ascendis Investigational Site Phoenix Arizona Recruiting
Ascendis Investigational Site Orange California Recruiting
Ascendis Investigational Site Sacramento California Recruiting
Ascendis Investigational Site San Francisco California Recruiting
Ascendis Pharma Investigational Site Centennial Colorado Recruiting
Ascendis Investigational Site Washington D.C. District of Columbia Recruiting
Ascendis Investigational Site Orlando Florida Recruiting
Ascendis Investigational Site Orlando Florida Recruiting
Ascendis Investigational Site Tampa Florida Recruiting
Ascendis Investigational Site Sandy Springs Georgia Recruiting
Ascendis Investigational Site Boise Idaho Recruiting
Ascendis Investigational Site Indianapolis Indiana Recruiting
Ascendis Investigational Site Iowa City Iowa Recruiting
Ascendis Investigational Site Louisville Kentucky Recruiting
Ascendis Investigational Site Minneapolis Minnesota Recruiting
Ascendis Investigational Site Las Vegas Nevada Recruiting
Ascendis Investigational Site Lebanon New Hampshire Recruiting
Ascendis Investigational Site Manchester New Hampshire Recruiting
Ascendis Investigational Site Morristown New Jersey Recruiting
Ascendis Investigational Site New Hyde Park New York Recruiting
Ascendis Investigational Site Cincinnati Ohio Recruiting
Ascendis Investigational Site Portland Oregon Recruiting
Ascendis Investigational Site Columbia South Carolina Recruiting
Ascendis Investigational Site Dallas Texas Recruiting
Ascendis Investigational Site El Paso Texas Recruiting
Ascendis Investigational Site Norfolk Virginia Recruiting
Ascendis Investigational Site Seattle Washington Recruiting

More Ascendis Pharma Endocrinology Division A/S trials in the USA

A Trial to Investigate Different Doses of Lonapegsomatropin Compared to Somatropin in Individuals With Turner Syndrome Active, not recruiting
A Post-Authorisation Safety Study (PASS) of Patients Treated With Lonapegsomatropin Recruiting

Other trials for the same condition

A Long-Term Safety Trial of LUM-201 in Children With Idiopathic Growth Hormone Deficiency Who Have Previously Completed a LUM-201 Clinical Trial (OraGrowtH211) Enrolling by invitation
A Post-Authorisation Safety Study (PASS) of Patients Treated With Lonapegsomatropin Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05820672 on ClinicalTrials.gov ↗ ← All trials in the USA